Navigation Links
ViroPharma To Acquire Lev Pharmaceuticals
Date:7/15/2008

e data from Lev's acute treatment trial was not presented before the BPAC and is currently under active review at FDA. On May 6, 2008, Lev announced that FDA accepted for review Lev's complete response submission for Cinryze targeting an action date of October 14, 2008.

About Hereditary Angioedema

HAE is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unrestricted, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. While there is no approved therapy for acute HAE attacks in the U.S., a commercially available C1 inhibitor has been used in Europe to treat HAE for more than 35 years. There are estimated to be 10,000 people with HAE in the U.S.

Additional information on HAE can be obtained from the U.S. Hereditary Angioedema Association at http://www.haea.org.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug developme
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 As the ... strong push within the industry to deliver better ... Organizations and pharma companies often means turning big ... Microtablets, developed in collaboration with Sensidose AB and ... can bring products to market sooner. The partnership ...
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
(Date:5/21/2013)... York, NY (PRWEB) May 21, 2013 Bed ... And according to My Cleaning Products, many turn to chemical-based ... because of the health and environmental risks those solutions present, ... with Bed Bug Bully instead. , According to ... bed bugs as they used to be. It shared that ...
(Date:5/21/2013)... Inflamax scientists worked closely with internationally ... the study, which will provide critical insight into ... in the study of allergy treatments, the Environmental ... models. Although both the models are well recognized ... direct comparison between the allergic responses evoked by ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... GlaxoSmithKline CEO, described the pharmaceutical group,s results as,"robust" in a ... GSK also announced that it will cease ... goals. , Describing 2008 as a ... make very clear what it would take to really make ...
... BETHESDA, Md., Feb. 5 Micromet, Inc. (Nasdaq: MITI ), ... at the BIO CEO and Investor Conference at the Waldorf-Astoria in New ... presentation will be available on the company,s website at www.micromet-inc.com ., ... Date: Tuesday, February 10, 2009, ...
... type 2 diabetes enters clinical developmentCARLSBAD, Calif., Feb. 5 ... announced today it has initiated a Phase 1 study ... of sodium dependent glucose co-transporter type 2 (SGLT2). ... in the kidney. Decreasing SGLT2 levels promotes glucose ...
Cached Biology Technology:Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009 2Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009 3Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009 4Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 2Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 3Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 4
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... New research suggests that a compound abundant in the ... death. , By altering a very specific step ... into normal cells that die as scheduled. , One ... process that would cause them to die on a ... study in cells, led by Ohio State University researchers, ...
(Date:5/19/2013)... novel study reports that white men and women of ... (hallux valgus) and lesser toe deformities, including hammer or ... to estimate the heritability of foot disorders in humansappear ... published by Wiley on behalf of the American College ... as many as 60% of older adults have foot ...
Breaking Biology News(10 mins):Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3Blame your parents for bunion woes 2
... American Geological Institute (AGI), in conjunction with its ... Needs for the Twenty First Century: The Role ... directions for the next President, his administration, federal ... identifies seven national issues and the role geosciences ...
... spiders are voracious predators and consume a wide range of ... have been proposed for why females eat males before or ... University in Ohio found, in a study published in the ... answer may be simpler than previously thought. Males are more ...
... A Florida State University researcher who uses high-powered computers ... mechanism that gives scientists a better understanding of how ... understanding eventually could lead to the development of new ... an assistant professor in FSU,s Department of Chemistry and ...
Cached Biology News:In spiders, size matters: Small males are more often meals 2Computational biochemist uncovers a molecular clue to evolution 2Computational biochemist uncovers a molecular clue to evolution 3
... ELISA Development kit contains the basic components ... to measure natural and recombinant canine Monocyte ... supernates and serum.1 Each kit contains sufficient ... 96-well plates, provided that the following conditions ...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Component of HyperMu™ Insertion Kit...
Recombinant Rhesus Macaque IFN-alpha...
Biology Products: